The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Open accessAbstract
OBJECTIVE: Cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. The primary end point was a change in HDL-cholesterol concentrations from baseline. Secondary/tertiary end points included changes in glycemic control, lipid profile, insulin sensitivity, body weight, liver triglyceride content, adipose tissue distribution, appetite, markers of inflammation, markers of vascular function, gut hormones, circulating endocannabinoids, and adipokine concentrations. Safety and tolerability end points were also evaluated. RESULTS: Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = −1.2 mmol/L; P < 0.05) and improved pancreatic β-cell function (HOMA2 β-cell function [ETD = −44.51 points; P < 0.01]), adiponectin (ETD = −5.9 × 106 pg/mL; P < 0.01), and apolipoprotein A (ETD = −6.02 μmol/L; P < 0.05), although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin (−898 pg/ml; P < 0.05) and increased glucose-dependent insulinotropic peptide (21.9 pg/ml; P < 0.05). None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated. CONCLUSIONS: THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Self-citationBergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Adiponectin – a key adipokine in the metabolic syndrome
Whitehead, J. P., Richards, A. A., Hickman, I. J., Macdonald, G. A., & Prins, J. B. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00510.x · Cited by 644
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horváth, B., Mukhopadhyay, B., Becker, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.033 · Cited by 499
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott, C., Izzo, A. A., & Di Marzo, V. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02338.x · Cited by 323
Self-citationResstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283
The endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
El-Remessy, A. B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.-T., Caldwell, R. B., & Liou, G. I. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050500 · Cited by 274
Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A. E., & Giagnoni, G. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-004-0871-3 · Cited by 242
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Schubart, C. D., Sommer, I. E. C., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 226
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., & Gallily, R. (2006) · Autoimmunity · doi:10.1080/08916930500356674 · Cited by 215
Rajesh, M., Mukhopadhyay, P., Bátkai, S., Haskó, G., Liaudet, L., Drel, V. R., Obrosova, I. G., & Pacher, P. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00236.2007 · Cited by 209
The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults
Penner, E. A., Buettner, H., & Mittleman, M. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.03.002 · Cited by 201
Thomas, A., Stevenson, L. A., Wease, K. N., Price, M. R., Baillie, G., Ross, R. A., & Pertwee, R. G. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706414 · Cited by 179
Time-dependent vascular actions of cannabidiol in the rat aorta
O'Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., & Kendall, D. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.010 · Cited by 177
Self-citationCannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis
De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B. Y., Scuderi, C., Sarnelli, G., Cuomo, R., Steardo, L., De Man, J. G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028159 · Cited by 173
Richardson, D., Ortori, C. A., Chapman, V., Kendall, D. A., & Barrett, D. A. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2006.10.039 · Cited by 169
Self-citationThe future of endocannabinoid-oriented clinical research after CB1 antagonists
Le Foll, B., Gorelick, D. A., & Goldberg, S. R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1506-7 · Cited by 167
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications
Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.11.003 · Cited by 162
Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., & Frey, W. H. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-16 · Cited by 160
Anavi‐Goffer, S., Baillie, G. L., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G., & Ross, R. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296020 · Cited by 159
Riedel, G., Fadda, P., McKillop‐Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00107.x · Cited by 152
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 147
Bolognini, D., Costa, B., Maione, S., Comelli, F., Marini, P., Marzo, V. D., Parolaro, D., Ross, R. A., Gauson, L. A., Cascio, M. G., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00756.x · Cited by 140
Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 133
Hill, A. J., Weston, S. E., Jones, N. A., Smith, I., Bevan, S. A., Williamson, E. M., Stephens, G. J., Williams, C. M., & Whalley, B. J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02523.x · Cited by 119
Wargent, E. T., Zaibi, M. S., Silvestri, C., Hislop, D. C., Stocker, C. J., Stott, C. G., Guy, G. W., Duncan, M., Marzo, V. D., & Cawthorne, M. A. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.9 · Cited by 115
Self-citationHugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors
Barter, P. J. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00041-7 · Cited by 114
Pertwee, R. G., Thomas, A., Stevenson, L. A., Ross, R. A., Varvel, S. A., Lichtman, A. H., Martin, B. R., & Razdan, R. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707124 · Cited by 105
Christopoulou, F., & Kiortsis, D. N. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01164.x · Cited by 99
Silvestri, C., Ligresti, A., & Marzo, V. D. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9167-3 · Cited by 92
The Metabolic Role of Retinol Binding Protein 4: An Update
Christou, G. A., Tselepis, A. D., & Kiortsis, D. N. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1295491 · Cited by 81
Beck depression inventory: Exploring its dimensionality in a nonclinical population
Endler, N. S., Rutherford, A., & Denisoff, E. (1999) · Journal of Clinical Psychology · doi:10.1002/(sici)1097-4679(199910)55:10<1307::aid-jclp11>3.0.co;2-7 · Cited by 67
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?
Foll, B. L., Trigo, J. M., Sharkey, K. A., & Strat, Y. L. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.01.019 · Cited by 58
Bátkai, S., Mukhopadhyay, P., Horváth, B., Rajesh, M., Gao, R. Y., Mahadevan, A., Mukkanti, A., Battista, N., Lichtman, A. H., Gauson, L. A., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01410.x · Cited by 48
Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes
Stanley, C. P., Wheal, A. J., Randall, M. D., & O’Sullivan, S. E. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.002 · Cited by 35
Self-citation
Cited by
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
New approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439
Phytocannabinoids: Origins and Biosynthesis
Gülck, T., & Møller, B. L. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2020.05.005 · Cited by 392
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
Metadata
- Authors
- Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., & Tan, G. D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-09-13
- Volume
- 39
- Issue
- 10
- Pages
- 1777-1786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2513568956
- Cited by
- 262
- References
- 43
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.